Extended-release mesalamine granules for ulcerative colitis;Gránulos de mesalamina de liberación prolongada para colitis ulcerativa

Annals of Pharmacotherapy

Volumn 46, Issue 11, 2012, Pages 1529-1536

  Love, Bryan L ^a   Miller, April D ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Apriso; Mesalamine granules; Salofalk; Ulcerative colitis

Indexed keywords

ANTACID AGENT; MESALAZINE; PROTON PUMP INHIBITOR;

ABNORMAL FECES; ALOPECIA; ARTICLE; BACKACHE; DIARRHEA; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FECES LEVEL; DRUG FORMULATION; DRUG GRANULE; DRUG RELEASE; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG URINE LEVEL; DYSPNEA; FATIGUE; HEADACHE; HUMAN; LIVER FAILURE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY (TOPIC); MYALGIA; NAUSEA; NEPHROTOXICITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RHINOPHARYNGITIS; SINGLE DRUG DOSE; TABLET FORMULATION; TINNITUS; TREATMENT DURATION; ULCERATIVE COLITIS; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VERTIGO;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DELAYED-ACTION PREPARATIONS; DRUG INTERACTIONS; HUMANS; MESALAMINE;

EID: 84869210721     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R171     Document Type: Article

References (28)

1. Kornbluth A, Sachar D; Gastroenterology PPCotACo. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010;105:501-23. doi: 10.1038/ajg.2009.727
2. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology 2008;135:1907-13. doi: 10.1053/j.gastro.2008.09.012
3. Kale-Pradhan PB, Pradhan RS, Wilhelm SM. Multi-Matrix System mesalamine: to use or not to use. Ann Pharmacother 2008;42:265-9. doi: 10.1345/aph.1K469
4. Moerike M. Inaccuracies concerning Salofalk granules. Aliment Pharmacol Ther 2011;34:824. doi: 10.1111/j.1365-2036.2011.04798.x
5. Product information. Apriso (mesalamine). Morrisville, NC: Salix Pharmaceuticals, Inc., February 2012.
6. Christensen LA, Fallingborg J, Abildgaard K, et al. Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man. Aliment Pharmacol Ther 1990;4:523-33.
7. Sandborn WJ. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention. Rev Gastroenterol Disord 2006;6:97-105.
8. Brunner M, Greinwald R, Kletter K, et al. Gastrointestinal transit and release of 5-aminosalicylic acid from 153Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers. Aliment Pharmacol Ther 2003;17:1163-9.
9. Safdi A, Pieniaszek H, Grigston A, Forbes W. Multiple-dose pharmacokinetics of granulated mesalamine, a unique formulation providing delayed and extended release of 5-ASA. Am J Gastroenterol 2008;103:S439-40.
10. Safdi AH, Grigston A, Forbes W. Minimal effect of a high fat meal on the pharmacokinetics of once-daily granulated mesalamine. Am J Gastroenterol 2008;103:S440.
11. Kruis W, Kiudelis G, Rácz I, et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, doubledummy, randomised, non-inferiority trial. Gut 2009;58:233-40. doi: 10.1136/gut.2008.154302
12. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989;298:82-6. doi: 10.1136/bmj.298.6666.82
13. Kruis W, Bar-Meir S, Feher J, et al. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clin Gastroenterol Hepatol 2003;1:36-43. doi: 10.1053/jcgh.2003.50006
14. Leifeld L, Pfützer R, Morgenstern J, et al. Mesalamine granules are superior to Eudragit-L-coated mesalamine tablets for induction of remission in distal ulcerative colitis-a pooled analysis. Aliment Pharmacol Ther 2011;34:1115-22. doi: 10.1111/j.1365-2036.2011.04840.x
15. Gross V, Bunganic I, Belousova EA, et al. 3g Mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial. J Crohns Colitis 2011;5:129-38. doi: 10.1016/j.crohns.2010.11.006
16. Lichtenstein GR, Gordon GL, Zakko S, et al. Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis: a 6-month placebo-controlled trial. Aliment Pharmacol Ther 2010;32:990-9. doi: 10.1111/j.1365-2036.2010.04438.x
17. Food and Drug Administration, Center for Drug Evaluation and Research. Summary review: Apriso (mesalamine granules). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022301s000_SumR.pdf (accessed 2012 Jun 22).
18. Lichtenstein GR, S. Zakko, Gordon GL, et al. Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomized controlled trials. Aliment Pharmacol Ther 2012;36:126-34. doi: 10.1111/j.1365-2036.2012.05142.x
19. Marakhouski Y, Fixa B, Holomán J, et al. A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. Aliment Pharmacol Ther 2005;21:133-40. doi: 10.1111/j.1365-2036.2005.02312.x
20. Encapsulated mesalamine granules (Apriso) for ulcerative colitis. Med Lett Drugs Ther 2009;51:38-9.
21. Gisbert JP, González-Lama Y, Maté J. 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 2007;13:629-38. doi: 10.1002/ibd.20099
22. Gupta MK, Pollack S, Hutchings JJ. Mesalamine induced symptom exacerbation of ulcerative colitis: case report and brief discussion. World J Gastrointest Pharmacol Ther 2010;1:132-4. doi: 10.4292/wjgpt.v1.i6.132
23. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 2002;51:536-9. doi: 10.1136/gut.51.4.536
24. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003; 114:39-43. doi: 10.1016/S0002-9343(02)01383-9
25. Prantera C, Rizzi M. 5-ASA in ulcerative colitis: improving treatment compliance. World J Gastroenterol 2009;15:4353-5. doi: 10.3748/wjg.15.4353
26. Han S, McColl E, Barton J, James P, Steen I, Welfare M. Predictors of quality of life in ulcerative colitis: the importance of symptoms and illness representations. Inflamm Bowel Dis 2005;11:24-34.
27. Velayos F, Terdiman J, Walsh J. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005;100:1345-53. doi: 10.1111/j.1572-0241.2005.41442.x
28. Goodrx.com. Drug pricing, Apriso/Asacol/Lailda. www.goodrx.com/price (accessed 2012 Oct 24).